9/16/11: AcuityBio, Inc. has been awarded a $1.4M Phase II SBIR grant

AcuityBio, Inc. has been awarded a prestigious $1.4M SBIR Phase II grant (2R44CA135967-02A1) from the National Cancer Institute of the National Institutes of Health following successful completion of a Phase I SBIR. The grant will help fund the remainder of preclinical development of the company's proprietary drug eluting ABC Mesh™. The company plans to apply to the US FDA for an IND and initiate first in human safety trials upon completion of the activities supported by the grant.

"The value of this grant goes way beyond the monetary value in two ways" said Jay Schwartz PhD, CEO. "This grant money will help us accelerate our ABC Mesh™ development plans and simultaneously validates the novelty of our technical approach to localized drug delivery. We are pleased that we are continuing to progress rapidly toward helping cancer patients live better quality and longer lives."

7/31/11: See AcuityBio at the "Soapbox Sessions" of the 38th Annual Meeting & Exposition of the Controlled Release Society

AcuityBio was accepted as one of only 20 new companies to speak at the prestigious Controlled Release Society's "Soapbox Sessions" this summer. For more information on this event, click here for more information.

6/2/11: See AcuityBio at this year's Massachusetts Life Sciences Innovation Day 2011

Come learn more about AcuityBio at this year's MALSI conference poster session on June 2nd. AcuityBio's President and CSO Jay Schwartz, was selected to be a Panel member for the event. Click here for more information.

5/3/11: Mass High Tech names AcuityBio one of "Five You Should Follow"

AcuityBio was nominated to be featured in Mass High Tech's weekly StartUp Report highlighting five startup companies and their busines goals... read more

4/22/11: AcuityBio's President Jay Schwartz is featured in Boston Business Journal

Jay speaks about the integral role that federal grant funding has had in accelerating progress and building value for AcuityBio. Read more in the April 22-28, 2011 issue (page 3) of the Boston Business Journal.

4/14/11: AcuityBio Presents at MTTC's Seventh Annual Early-Stage Life Sciences Technology Conference

AcuityBio was pleased to be selected as one of sixteen early stage life science companies to present at the Massachusetts Technology Transfer Center's annual conference. The conference showcased an array of exciting up-and-coming technologies ranging from web tools for keeping a healthy life style to novel cancer therapies... view program

7/28/10: "Boston University Names First Innovator-of-the-Year"

Boston University Professor and AcuityBio co-founder Mark W. Grinstaff has won the inaugural Innovator-of-the-Year Award from BU's Office of Technology Development, recognizing a faculty member who translates research into innovations that benefit humankind... read more

3/10: "New Drug Delivery Method for Preventing Recurrence of Local Lung Tumor"

CIMIT investigators use a low-dose chemotherapeutic polymer film to deliver drugs directly to lung tissue following surgical resection of a tumor... read more